Arvinas, Inc (ARVN) is a publicly traded Healthcare sector company. As of May 21, 2026, ARVN trades at $9.10 with a market cap of $566.50M and a P/E ratio of -1.34. ARVN moved +6.43% today. Year to date, ARVN is -18.53%; over the trailing twelve months it is +37.05%. Its 52-week range spans $5.90 to $29.61. Analyst consensus is buy with an average price target of $15.20. Rallies surfaces ARVN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Barclays Raises Arvinas Price Target to $20 After VEPPANU Approval: Arvinas reported downbeat first-quarter results, prompting several analysts to raise their earnings forecasts despite a wider net loss. Barclays lifted its price target to $20, citing FDA approval of VEPPANU and an $85 million upfront licensing deal with Pfizer and Rigel plus up to $320 million in milestones.
| Metric | Value |
|---|---|
| Price | $9.10 |
| Market Cap | $566.50M |
| P/E Ratio | -1.34 |
| EPS | $-6.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $29.61 |
| 52-Week Low | $5.90 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $78.50M |
| Net Income | $-367.30M |
| Gross Margin | 0.00% |
17 analysts cover ARVN: 0 strong buy, 9 buy, 7 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.20.